There’s a lot of noise around GLP-1s. Let’s separate the medication, the evidence, and the care.
Semaglutide works on the GLP-1 pathway.
Semaglutide acts on a pathway involved in appetite, digestion, and blood-sugar regulation. FDA-approved semaglutide products exist for specific conditions; the exact product and its suitability are clinical decisions.
Your medication’s formulation, label, and instructions matter. A compounded product is not the same as an FDA-approved product.
Open the semaglutide PDF guide ↗Tirzepatide acts on two pathways.
Tirzepatide acts on both GIP and GLP-1 pathways. FDA-approved tirzepatide injections exist for specific conditions. It is a different medication from semaglutide, with its own labeling and care considerations.
The prescribing care team selects the treatment plan and any adjustments. Personal questions about other medicines—including oral hormonal contraception—belong with that team.
Open the tirzepatide PDF guide ↗Retatrutide belongs in the research conversation.
Retatrutide is being studied as a triple agonist targeting GIP, GLP-1, and glucagon receptors. It is not an FDA-approved medication.
Published trial doses and schedules are not instructions for personal use. Products marketed online as “research use only” should not be treated as approved medicines.
Research status: Lilly’s retatrutide information. This section is educational and is not an offer of treatment.
Open the research PDF guide ↗A study average isn’t a personal promise.
This guide highlights STEP 1, SURMOUNT-1, SELECT, and retatrutide research. They answer different questions, in different groups, over different periods.
Studied weight change over 68 weeks.
Studied weight change over 72 weeks.
Studied a specific group with existing cardiovascular disease, overweight or obesity, and no diabetes.
Separate trials do not establish a head-to-head ranking. Results depend on the population, treatment, follow-up period, and outcome being measured. Individual results vary.
Care continues after the prescription.
The program includes clinical review, pharmacy fulfillment, early coaching, and ongoing follow-up. Here’s how that journey is presented:
A licensed clinician reviews history, medicines, conditions, and goals.
The selected medication arrives with product-specific instructions.
Discuss progress, side effects, and the care plan.
Follow-up, appropriate labs, nutrition, sleep, coaching, and care-team contact.
Confirm current access, included services, and timing with the clinical program.
Personal medical questions need a clinical answer.
Side effects, medical history, pregnancy plans, other medicines, and product-specific warnings all matter. Review them with the prescribing clinician and read the information supplied with your medication.
Do not change the dose, concentration, schedule, or formulation without the prescribing care team. For an emergency, call 911.
Read the medication safety information ↗Compounded medications are not FDA-approved. Read the FDA’s information about unapproved GLP-1 drugs.
The right question goes to the right person.
Understanding the program and deciding on treatment are separate steps. Enrollment does not guarantee a prescription.
Better questions.
A more informed decision.
Explore how the program fits together, then review the next steps with your questions in hand.
Explore the program guide →Does this guide choose a medication for me?
No. A licensed clinician evaluates suitability and selects any appropriate treatment.
Can I compare trial percentages directly?
Different trials involve different participants, methods, and follow-up periods. Separate trial results are not a head-to-head comparison.
Can SvelteRX change my prescription?
No. Changes to your medication or instructions belong with the prescribing care team.